Icosavax_Logo.jpg
Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults
04 oct. 2022 16h05 HE | Icosavax, Inc.
- IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage - - Phase 1 topline interim...
Icosavax_Logo.jpg
Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update
15 août 2022 16h05 HE | Icosavax, Inc.
– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial...
Icosavax_Logo.jpg
Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones
28 juil. 2022 16h05 HE | Icosavax, Inc.
- Antigen component of IVX-411 found to be unstable; issue specific to molecule, with no evidence of read-through to other Icosavax programs - - Now focused on a bivalent strategy for COVID-19...
Icosavax_Logo.jpg
Icosavax to Participate in the William Blair Biotech Focus Conference
06 juil. 2022 16h05 HE | Icosavax, Inc.
SEATTLE, July 06, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax_Logo.jpg
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV
28 juin 2022 16h05 HE | Icosavax, Inc.
- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well...
Icosavax_Logo.jpg
Icosavax to Participate in the Jefferies Healthcare Conference
01 juin 2022 16h05 HE | Icosavax, Inc.
SEATTLE, June 01, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop combination...
Icosavax_Logo.jpg
Icosavax Reports First Quarter 2022 Financial Results and Provides Corporate Update
16 mai 2022 16h05 HE | Icosavax, Inc.
- Enrollment completed in older adults portion of Phase 1/1b trial of IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F...
Icosavax_Logo.jpg
Icosavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
30 mars 2022 16h15 HE | Icosavax, Inc.
- Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - -...
Icosavax_Logo.jpg
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
25 mars 2022 08h00 HE | Icosavax, Inc.
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology;...
Icosavax_Logo.jpg
Icosavax to Participate in the Cowen 42nd Annual Health Care Conference
02 mars 2022 08h00 HE | Icosavax, Inc.
SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...